by Laurie Erickson.
After a successful Phase 1b trial of its tendinopathy treatment called TenoMIR, Causeway Therapeutics has acquired $8.75 million to conduct a Phase 2 trial in the USA, Netherlands, and the UK. The TenoMIR treatment is a small molecule therapy that simulates natural miR29a, which is decreased in tendinopathy and leads to a decrease in the healthy Type 1 to Type 3 collagen ratio. Restoring levels of miR29a helps to restore the Type 1 collagen and heal the tendon. The trial is one of two that are required before TenoMIR can be registered as a drug to treat tendinopathy. This Phase 2 trial will include athletes and non-athletes with tennis elbow.
More information about the trial can be found at the University of Glasgow site (Causeway Therapeutics is a spin-off company started at University of Glasgow).